

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM442779

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
SILICON VALLEY BANK		08/31/2017	Corporation: CALIFORNIA
RECEIVING PARTY DATA			
Name:	GANEDEN BIOTECH, INC.		
Street Address:	5800 Landerbrook Drive		
City:	Mayfield Heights		
State/Country:	OHIO		
Postal Code:	44124		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 21			
Property Type	Number	Word Mark	
Serial Number:	85151721	BC30	
Serial Number:	85558085	SCIENCE INSPIRED BEAUTY	
Serial Number:	85558082	BONICEL	
Registration Number:	4130573	INTENSIVE BOWEL SUPPORT	
Serial Number:	85109434	ENLIVEN	
Registration Number:	3947961		
Registration Number:	3126420	DIGESTIVE ADVANTAGE	
Registration Number:	3173561	ARTHRITIS ADVANTAGE	
Registration Number:	3170953	DERMAL ADVANTAGE	
Registration Number:	3129369	NAIL ADVANTAGE	
Registration Number:	3918794	IMMUNE ADVANTAGE	
Registration Number:	3794310	GANPRO	
Registration Number:	3962293	GANEDEN BC30 PROBIOTIC POWERED BY DIGEST	
Registration Number:	3758318	THE PROLIFIC PROBIOTIC	
Registration Number:	3412151	SUSTENEX	
Registration Number:	3591766	GANEDENBC30	
Registration Number:	2449113	CLEARLY CONFIDENT	
Registration Number:	2403460	GANEDEN	
Serial Number:	85003349	I.B. DEFENSE FORMULA	

CH \$540.00 85151721

Property Type	Number	Word Mark
Serial Number:	85003270	LACTOSE DEFENSE FORMULA
Serial Number:	85955557	BONICEL

CORRESPONDENCE DATA

Fax Number: 3142592020
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Phone: 3142592000
Email: bcipdocketing@bryancave.com
Correspondent Name: BRYAN CAVE LLP
Address Line 1: 211 North Broadway, Suite 3600
Address Line 4: St. Louis, MISSOURI 63102

NAME OF SUBMITTER:	Mark A. Paskar
SIGNATURE:	/Mark A. Paskar/
DATE SIGNED:	09/12/2017

Total Attachments: 10
source=19a-i - SVB USPTO Release#page1.tif
source=19a-i - SVB USPTO Release#page2.tif
source=19a-i - SVB USPTO Release#page3.tif
source=19a-i - SVB USPTO Release#page4.tif
source=19a-i - SVB USPTO Release#page5.tif
source=19a-i - SVB USPTO Release#page6.tif
source=19a-i - SVB USPTO Release#page7.tif
source=19a-i - SVB USPTO Release#page8.tif
source=19a-i - SVB USPTO Release#page9.tif
source=19a-i - SVB USPTO Release#page10.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (the "Release") is made as of the 31 day of August, 2017, between GANEDEN BIOTECH, INC., a Delaware corporation ("Assignee"), and SILICON VALLEY BANK, a California corporation ("Assignor").

WHEREAS, in connection with certain loan documents, Assignee and Assignor entered into the Second Amended and Restated Loan and Security Agreement dated as of October 31, 2014 (as amended, supplemented, or otherwise modified from time to time, the "Loan Agreement") and the Intellectual Property Security Agreement dated as of October 5, 2012 (as amended, supplemented, or otherwise modified from time to time, the "IP Agreement"; together with the Loan Agreement, collectively, the "Agreements") for the purpose of securing certain obligations of Assignee to Assignor;

WHEREAS, pursuant to the Agreements, Assignee granted Assignor, for the benefit of Assignor, a security interest in all of the Patents, Trademarks, and Copyrights (as defined in the Agreements) (collectively hereinafter the "Intellectual Property"), including the Patents, Trademarks, and Copyrights, identified on Exhibits A, B, and C, attached hereto, and pledged and mortgaged (but did not transfer title to) the Intellectual Property to Assignor; and

WHEREAS, all of the indebtedness and other obligations secured by the Assignor's security interest in the Intellectual Property have been repaid in their entirety, and the Assignor is therefore obligated to release its security interest in the Intellectual Property.

NOW, THEREFORE, for valuable consideration and pursuant to the terms and conditions set forth in the Agreements:

The Assignor hereby terminates and releases its security interest in the Intellectual Property, including, without limitation, the Patents, Trademarks, and Copyrights identified on Exhibits A, B, and C attached hereto, and the Assignor hereby assigns and transfers to Assignee, without any representation, warranty, or recourse whatsoever, the Assignor's entire right, title, and interest in and to the Intellectual Property, effective as of the date set forth above.

Assignor hereby agrees to execute such further instruments and documents and perform such further acts as Assignee may deem necessary to secure to Assignee the rights herein conveyed.

"ASSIGNOR"

SILICON VALLEY BANK


By: 
Name: John Hensley
Title: Director

EXHIBIT A - PATENTS

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
PROBIOTIC, LACTIC ACID- PRODUCING BACTERIA AND USES THEREOF	8,097,247	January 17, 2012
METHODS AND COMPOSITIONS FOR THE DIETARY MANAGEMENT OF AUTOIMMUNE DISORDERS	7,854,927	December 21, 2010
METHODS OF INHIBITING GROWTH OF BACTERIA, YEAST, FUNGUS, AND VIRUS WITH PSEUDOMONAS LINDBERGII AND BACILLUS COAGULANS EXTRACELLULAR PRODUCTS	7,807,185	October 5, 2010
PROBIOTIC, LACTIC ACID- PRODUCING BACTERIA AND USES THEREOF	7,807,151	October 5, 2010
METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	7,767,203	August 3, 2010
INHIBITION OF PATHOGENS BY PROBIOTIC BACTERIA	7,713,726	May 11, 2010
PROBIOTIC, LACTIC ACID- PRODUCING BACTERIA AND USES THEREOF	7,708,988	May 4, 2010
METHODS FOR INCREASING LACTOSE DIGESTION	7,700,093	April 20, 2010
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	7,544,363	June 9, 2009
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	7,541,042	June 2, 2009
TOPICAL USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS	7,507,402	March 24, 2009
PROBIOTIC LACTIC ACID BACTERIUM TO TREAT BACTERIAL INFECTIONS ASSOCIATED WITH SIDS	7,374,753	May 20, 2008

USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS AND PREPARATIONS	7,371,407	May 13, 2008
METHODS FOR REDUCING CHOLESTEROL USING BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS	7,232,571	June 19, 2007
USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS AND PREPARATIONS	7,048,950	May 23, 2006
ABSORBENT PRODUCT CONTAINING ABSORBENT STRUCTURE AND BACILLUS COAGULANS	7,025,974	April 11, 2006
TOPICAL COMPOSITIONS CONTAINING PROBIOTIC BACILLUS BACTERIA, SPORES, AND EXTRACELLULAR PRODUCTS AND USES THEREOF	6,905,692	June 14, 2005
INHIBITION OF PATHOGENS BY PROBIOTIC BACTERIA	6,849,256	February 1, 2005
METHODS FOR REDUCING CHOLESTEROL USING BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS	6,811,786	November 2, 2004
USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS & PREPARATIONS	6,733,751	May 11, 2004
TOPICAL COMPOSITIONS CONTAINING PROBIOTIC BACILLUS BACTERIA, SPORES, AND EXTRACELLULAR PRODUCTS AND USES THEREOF	6,723,326	April 20, 2004
ABSORBENT PRODUCT CONTAINING ABSORBENT STRUCTURE AND BACILLUS COAGULANS	6,716,435	April 6, 2004
TOPICAL COMPOSITIONS CONTAINING EXTRACELLULAR PRODUCTS OF PSEUDOMONAS LINDBERGHII AND EMU OIL	6,645,506	November 11, 2003

USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS AND PREPARATIONS	6,531,126	March 11, 2003
PROBIOTIC, LACTIC ACID-PRODUCING BACTERIA AND USES THEREOF	6,461,607	October 8, 2002
INHIBITION OF PATHOGENS BY PROBIOTIC BACTERIA	20110189145 12/756658	April 8, 2010
METHODS AND COMPOSITIONS FOR THE DIETARY MANAGEMENT OF AUTOIMMUNE DISORDERS	20110064708 12/951859	November 22, 2010
PROBIOTIC, LACTIC ACID-PRODUCING BACTERIA AND USES THEREOF	20110020305 12/897590	October 4, 2010
PROBIOTIC CONFECTION AND LIPID COMPOSITIONS	20110256216 13/086675	April 14, 2011
BEVERAGE COMPOSITIONS	20110195154 13/087803	April 15, 2011
PROBIOTIC, LACTIC ACID-PRODUCING BACTERIA AND USES THEREOF	20110020306 12/897604	October 4, 2010
INACTIVATED BACTERIAL CELL FORMULATION	20100297092 12/770457	April 29, 2010
PROBIOTIC GRAIN-BASED COMPOSITIONS	20100210000 12/580622	October 16, 2009
COMPOSITIONS AND METHODS FOR CLEANING SURFACES	20090305387 12/363442	January 30, 2009
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	20090238907 12/479064	September 24, 2009
COMPOSITIONS AND METHODS FOR ENHANCING PAPER PRODUCT DEGRADATION	20090191609 12/229842	August 27, 2008
TOPICAL USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS	20090186057 12/370255	February 12, 2009
METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	20090181000 12/365798	February 4, 2009

METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	20090142315 12/365808	February 4, 2009
BAKED GOODS	20090186126 12/229862	August 27, 2008
BEVERAGE COMPOSITIONS	20090232941 12/253048	October 16, 2008
METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	20080112942 11/985617	November 15, 2007
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	20080089963 11/974427	October 12, 2007
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	20050271758 11/152894	June 14, 2005
PROBIOTIC LACTIC ACID BACTERIUM TO TREAT BACTERIAL INFECTIONS ASSOCIATED WITH SIDS	20080193429 12/148200	April 17, 2008
USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS & PREPARATIONS	20080274153 12/080402	April 1, 2008
INHIBITION OF PATHOGENS BY PROBIOTIC BACTERIA	20050232909 11/005897	December 6, 2004
PROBIOTIC, LACTIC ACID- PRODUCING BACTERIA AND USES THEREOF	20030031659 10/264745	October 4, 2002
PROBIOTIC COMPOSITIONS	20030124104 10/287904	November 5, 2002
PROBIOTIC CONFECTION AND LIPID COMPOSITIONS	PCT/US2011/032449	April 14, 2011
INACTIVATED BACTERIAL CELL FORMULATION	PCT/US2010/032993	April 29, 2010

PROBIOTIC GRAIN-BASED COMPOSITIONS	PCT/US2009/060983	October 16, 2009
COMPOSITIONS AND METHODS FOR CLEANING SURFACES	PCT/US2009/000608	January 30, 2009
BEVERAGE COMPOSITIONS	PCT/US2008/011812	October 16, 2008
COMPOSITIONS AND METHODS FOR ENHANCING PAPER PRODUCT DEGRADATION	PCT/US2008/010141	August 27, 2008
BAKED GOODS	PCT/US2008/010143	August 27, 2008
METHODS AND COMPOSITIONS FOR THE DIETARY MANAGEMENT OF AUTOIMMUNE DISORDERS	PCT/US2005/016469	May 11, 2005
INHIBITION OF PATHOGENS BY BACILLUS COAGULANS STRAINS	PCT/US2000/030737	November 8, 2000
USE OF EMU OIL A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS	PCT/US2000/023448	August 25, 2000
IMPROVED TOPICAL COMPOSITIONS CONTAINING PROBIOTIC BACTERIA, SPORES, AND EXTRACELLULAR PRODUCTS AND USES THEREOF	PCT/US2000/023300	August 25, 2000
METHODS FOR INHIBITING MICROBIAL INFECTIONS ASSOCIATED WITH SANITARY PRODUCTS	PCT/US2000/010222	April 14, 2000
PROBIOTIC, LACTIC ACID-PRODUCING BACTERIA AND USES THEREOF	PCT/US1999/017862	August 6, 1999
METHODS FOR INCREASING THE SOLUBILITY OF NUTRITIONAL MATERIALS USING PROBIOTIC LACTIC ACID-PRODUCING BACTERIA	PCT/US1999/017671	August 6, 1999
METHODS FOR REDUCING CHOLESTEROL USING (BACILLUS COAGULANS) SPORES, SYSTEMS AND COMPOSITIONS	PCT/US1999/007360	April 1, 1999
PROBIOTIC LACTIC ACID BACTERIUM TO TREAT BACTERIAL INFECTIONS ASSOCIATED WITH SIDS	PCT/US1998/011347	June 3, 1998
TOPICAL USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS	PCT/US1998/007307	April 10, 1998

METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	PCT/US2004/040513	December 3, 2004
METHODS FOR REDUCING CHOLESTEROL USING BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS	8,349,337	JANUARY 8, 2013
PROBIOTIC SPORTS NUTRITION COMPOSITIONS	13/434,401	MARCH 29, 2012
INACTIVATED BACTERIAL CELL FORMULATION	13/613,316	SEPTEMBER 13, 2012
PROBIOTIC, LACTIC ACID- PRODUCING BACTERIA	13/423,852	MARCH 19, 2012
PROBIOTIC SPORTS NUTRITION COMPOSITIONS	PCT/US2012/031210	MARCH 29, 2012

EXHIBIT B -- TRADEMARKS

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
BC30	85/151721	October 13, 2010
SCIENCE INSPIRED BEAUTY	85/558085	March 1, 2012
BONICEL	85/558082	March 1, 2012
INTENSIVE BOWEL SUPPORT	4,130,573	April 24, 2012
ENLIVEN	85/109434	August 17, 2010
DESIGN ONLY	3,947,961	April 19, 2011
DIGESTIVE ADVANTAGE	3,126,420	August 8, 2006
ARTHRITIS ADVANTAGE	3,173,561	November 21, 2006
DERMAL ADVANTAGE	3,170,953	November 14, 2006
NAIL ADVANTAGE	3,129,369	August 15, 2006
IMMUNE ADVANTAGE	3,918,794	February 15, 2011
GANPRO	3,794,310	May 25, 2010
GANEDEN BC30 PROBIOTIC POWERED BY DIGESTIVE & IMMUNE HEALTH	3,962,293	May 17, 2011
THE PROLIFIC PROBIOTIC	3,758,318	March 9, 2010
SUSTENEX	3,412,151	April 15, 2008
GANEDENBC30	3,591,766	March 17, 2009
CLEARLY CONFIDENT	2,449,113	May 8, 2001
GANEDEN	2,403,460	November 14, 2000
I.B. DEFENSE FORMULA	85/003349	March 31, 2010
LACTOSE DEFENSE FORMULA	85/003270	March 31, 2010
GANENDEN BC 30	CA156968200	March 14, 2012
GANEDEN BC 30 CULTURES DESIGN	CA154547600	September 22, 2011
ENLIVEN	CA151615600	February 17, 2011
LACTOSE DEFENSE FORMULA	CA149996000	September 30, 2010

GANEDEN BC30 PROBIOTIC POWERED BY DIGESTIVE & IMMUNE HEALTH	CA144904700	August 14, 2009
THE PROLIFIC PROBIOTIC	CA141563700	October 23, 2008
DIGESTIVE ADVANTAGE	CA135049300	June 6, 2007
GANEDENBC30 DESIGN	CA134471200	April 24, 2007
SUSTENEX	CA134452000	April 23, 2007
GANEDEN BC 30 CULTURES	EC010114106	July 11, 2011
ENLIVEN	EC009948324	May 6, 2011
LACTOSE DEFENSE FORMULA	EC009413121	September 30, 2010
I.B. DEFENSE FORMULA	EC009413171	September 30, 2010
THE PROLIFIC PROBIOTIC	EC007338064	October 23, 2008
DIGESTIVE ADVANTAGE	EC005953104	May 30, 2007
GANEDENBC30	EC005850797	April 23, 2007
SUSTENEX	EC005850086	April 23, 2007
ENLIVEN	WO01069997	February 17, 2011
BONICEL	85/955,557	June 10, 2013

EXHIBIT C – COPYRIGHTS

None